SPY756.62−0.42%QQQ686.17−0.61%BTC/USD71,511.00−3.27%DIA524.31−0.02%GLD356.89−2.27%TLT80.65−0.34%

Janux Therapeutics Inc

JANXNASDAQ

Trade with Public

$11.67

-0.72-5.81%

Last update: Nov 12, 9:38 AM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Earnings: Q3 2026 Earnings were released on Thu Nov 5th, after the market close

Janux Therapeutics (JANX) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Janux Therapeutics (JANX) stock.

Analyst Consensus — 17 Analysts

16Buy

1Hold

# Analysts17

Latest Upgrades and Downgrades for Janux Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Truist Securities	Supawat Thongthip	PT Raise	Buy	$26→$27
—	Wedbush	Robert Driscoll	PT Raise	Outperform	$36→$40
—	Barclays	Etzer Darout	PT Raise	Underweight	$14→$15
—	Wolfe Research	Kalpit Patel	Upgrade	Peer Perform→Outperform	$23
—	Guggenheim	Brad Canino	PT Cut	Buy	$58→$55
—	Truist Securities	Supawat Thongthip	Assumes	Buy	$80→$26
—	Piper Sandler	Kelsey Goodwin	PT Cut	Overweight	$30→$26
—	Wedbush	Robert Driscoll	PT Cut	Outperform	$45→$36
—	Guggenheim	Brad Canino	PT Cut	Buy	$68→$58
—	Jones Trading	Boris Peaker	PT Cut	Buy	$50→$28
—	Barclays	Etzer Darout	Downgrade	Overweight→Underweight	$29→$14
—	UBS	David Dai	Downgrade	Buy→Neutral	$57→$15
—	Cantor Fitzgerald	Josh Schimmer	PT Cut	Overweight	$150→$100
—	Guggenheim	Brad Canino	PT Cut	Buy	$72→$68
—	Clear Street	Kaveri Pohlman	Downgrade	Buy→Hold	$32→$12
—	Piper Sandler	Kelsey Goodwin	PT Cut	Overweight	$42→$30
—	Barclays	Etzer Darout	PT Cut	Overweight	$48→$29
—	Stifel	Bradley Canino	PT Cut	Buy	$46→$38
—	Clear Street	Kaveri Pohlman	PT Cut	Buy	$80→$32
—	B of A Securities	Geoff Meacham	PT Cut	Buy	$58→$49

Janux Therapeutics Inc

Janux Therapeutics (JANX) Stock Price Target 2026

Latest Upgrades and Downgrades for Janux Therapeutics Stock

Janux Therapeutics (JANX) Stock Price Target 2026

Latest Upgrades and Downgrades for Janux Therapeutics Stock

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PRO
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PRO
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PRO
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PRO
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

Janux Therapeutics Inc

Janux Therapeutics (JANX) Stock Price Target 2026

Latest Upgrades and Downgrades for Janux Therapeutics Stock

Janux Therapeutics (JANX) Stock Price Target 2026

Latest Upgrades and Downgrades for Janux Therapeutics Stock

Analyst Ratings News

PROTruist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PROWedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PROBarclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PROWolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PROGuggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

People Also Watch

People Also Watch

Analyst Ratings News

PROTruist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PROWedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PROBarclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PROWolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PROGuggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

PRO
Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PRO
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PRO
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

PRO
Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PRO
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PRO
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55